These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 12614183)

  • 21. Economic costs for adult asthmatics according to severity and control status in Korean tertiary hospitals.
    Kim SH; Kim TW; Kwon JW; Kang HR; Lee YW; Kim TB; Kim SH; Park HW; Park SW; Chang YS; Cho YS; Park JW; Cho YJ; Yoon HJ; Cho SH; Choi BW; Moon HB; Min KU
    J Asthma; 2012 Apr; 49(3):303-9. PubMed ID: 22185405
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Asthma and Chronic Obstructive Pulmonary Disease Overlap Syndrome: Doubled Costs Compared with Patients with Asthma Alone.
    Gerhardsson de Verdier M; Andersson M; Kern DM; Zhou S; Tunceli O
    Value Health; 2015 Sep; 18(6):759-66. PubMed ID: 26409602
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Poor control increases the economic cost of asthma. A multicentre population-based study.
    Accordini S; Bugiani M; Arossa W; Gerzeli S; Marinoni A; Olivieri M; Pirina P; Carrozzi L; Dallari R; De Togni A; de Marco R
    Int Arch Allergy Immunol; 2006; 141(2):189-98. PubMed ID: 16899987
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The pharmacoeconomics of asthma].
    Plaza Moral V
    Arch Bronconeumol; 1999 May; 35 Suppl 3():22-6. PubMed ID: 10410220
    [No Abstract]   [Full Text] [Related]  

  • 25. Development of an economic model to assess the cost effectiveness of asthma management strategies.
    Price MJ; Briggs AH
    Pharmacoeconomics; 2002; 20(3):183-94. PubMed ID: 11929348
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A cost-effectiveness analysis of first-line controller therapies for persistent asthma.
    Shih YC; Mauskopf J; Borker R
    Pharmacoeconomics; 2007; 25(7):577-90. PubMed ID: 17610338
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The complexity of treatment adherence in adults with asthma: challenges and opportunities.
    Schmier JK; Leidy NK
    J Asthma; 1998; 35(6):455-72. PubMed ID: 9751063
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Healthcare costs and resource utilization of asthma in Germany: a claims data analysis.
    Jacob C; Bechtel B; Engel S; Kardos P; Linder R; Braun S; Greiner W
    Eur J Health Econ; 2016 Mar; 17(2):195-201. PubMed ID: 25716136
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Asthma treatment guidelines: how do we measure up?
    Navarro RP
    Am J Manag Care; 2005 Nov; 11(14 Suppl):S422-6; quiz S427-33. PubMed ID: 16300463
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The influence of structured information and monitoring on the outcome of asthma treatment in primary care: a cluster randomized study.
    Nokela M; Arnlind MH; Ehrs PO; Krakau I; Forslund L; Jonsson EW
    Respiration; 2010; 79(5):388-94. PubMed ID: 19672055
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effects on prescribing patterns and costs of having a special interest in asthma.
    Jones KP; Harris CM; Bogle SM; Foley R; Usherwood TP
    J R Soc Med; 1995 Oct; 88(10):570-5. PubMed ID: 8537947
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Empowering pharmacists in asthma management through interactive SMS (EmPhAsIS): study protocol for a randomized controlled trial.
    De Vera MA; Sadatsafavi M; Tsao NW; Lynd LD; Lester R; Gastonguay L; Galo J; FitzGerald JM; Brasher P; Marra CA
    Trials; 2014 Dec; 15():488. PubMed ID: 25494702
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of asthma controller medications on medical and economic resource utilization in adult asthma patients.
    Lee TA; Chang CL; Stephenson JJ; Sajjan SG; Maiese EM; Everett S; Allen-Ramey F
    Curr Med Res Opin; 2010 Dec; 26(12):2851-60. PubMed ID: 21070096
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Quality assurance of drug therapy for patients with asthma. Health economic analysis].
    Søndergaard B; Thorleifsson S; Herborg H; Frøkjaer B; Hepler CD; Ersbøll BK
    Ugeskr Laeger; 2000 Jan; 162(4):480-6. PubMed ID: 10697444
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Concepts in studying cost effectiveness of pediatric asthma treatment in Germany, Switzerland and Austria].
    Frischer T; Sennhauser FH; Fischer JE; Szucs T; Köck C
    Wien Med Wochenschr; 2003; 153(3-4):59-64. PubMed ID: 12658964
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Pharmacoeconomics of chronic obstructive pulmonary disease].
    Jahnz-Rózyk K
    Pneumonol Alergol Pol; 2009; 77(3):302-4. PubMed ID: 19591104
    [No Abstract]   [Full Text] [Related]  

  • 37. Costs associated with asthma treatment.
    Barbers R
    Curr Opin Pulm Med; 1998 Jan; 4(1):1-3. PubMed ID: 9526897
    [No Abstract]   [Full Text] [Related]  

  • 38. Economic burden of asthma: a systematic review.
    Bahadori K; Doyle-Waters MM; Marra C; Lynd L; Alasaly K; Swiston J; FitzGerald JM
    BMC Pulm Med; 2009 May; 9():24. PubMed ID: 19454036
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A 36-month study on the cost/utility of add-on omalizumab in persistent difficult-to-treat atopic asthma in Italy.
    Dal Negro RW; Tognella S; Pradelli L
    J Asthma; 2012 Oct; 49(8):843-8. PubMed ID: 22954018
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Factors affecting UK primary-care costs of managing patients with asthma over 5 years.
    Dasgupta R; Guest JF
    Pharmacoeconomics; 2003; 21(5):357-69. PubMed ID: 12627989
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.